Table 1.
Baseline characteristics of participants
| Characteristics | Total Sample (N = 95) | CBT-I + Placebo (N = 24) | CBT-I + Armodafinil (N = 23) | Armodafinil (N = 24) | Placebo (N = 24) | |
|---|---|---|---|---|---|---|
| Age | Mean (SD) | 56.2 (9.9) | 58.9 (9.9) | 56.3 (10.0) | 57.1 (7.4) | 52.8 (11.5) |
| Range | 26–75 | 30–74 | 36–73 | 43–75 | 26–69 | |
| Gender | Female | 84 (88.4%) | 21 (87.5%) | 22 (95.7%) | 23 (95.8%) | 18 (75.0%) |
| Male | 11 (11.6%) | 3 (12.5%) | 1 (4.3%) | 1 (4.2%) | 6 (25.0%) | |
| Race | White | 86 (90.5%) | 23 (95.8%) | 21 (91.3%) | 23 (95.8%) | 19 (79.2%) |
| African American | 8 (8.4%) | 1 (4.2%) | 2 (8.7%) | 1 (4.2%) | 4 (16.7%) | |
| Unknown | 1 (1.1%) | – | – | – | 1 (4.2%) | |
| Ethnicity | Non-Hispanic/Latino | 90 (94.7%) | 23 (95.8%) | 22 (95.7%) | 22 (91.7%) | 23 (95.8%) |
| Unknown | 5 (5.3%) | 1 (4.2%) | 1 (4.3%) | 2 (8.3%) | 1 (4.2%) | |
| Education | Bachelor’s or higher | 47 (49.5%) | 10 (41.7%) | 14 (60.9%) | 13 (54.2%) | 10 (41.7%) |
| Partial college training | 37 (38.9%) | 10 (41.7%) | 5 (21.7%) | 10 (41.7%) | 12 (50.0%) | |
| High school graduate or less | 10 (10.6%) | 4 (16.7%) | 3 (13.0%) | 1 (4.2%) | 2 (8.3%) | |
| Cancer Type | Breast Cancer | 65 (68.4%) | 16 (66.7%) | 17 (73.9%) | 17 (70.8%) | 15 (62.5%) |
| Blood Cancer | 9 (9.5%) | 4 (16.7%) | 1 (4.3%) | – | 4 (16.7%) | |
| Brain & Peripheral Nervous System Tumor | 2 (2.1%) | 1 (4.2%) | – | 1 (4.2%) | – | |
| Head & Neck Cancer | 6 (6.3%) | – | 4 (17.4%) | 2 (8.3%) | – | |
| Alimentary Track Cancer | 6 (6.3%) | – | 1 (4.3%) | 3 (12.5%) | 2 (8.3%) | |
| Genitourinary Tract Cancer | 3 (3.2%) | 1 (4.2%) | – | – | 2 (8.3%) | |
| Gynecologic Cancer | 3 (3.2%) | 1 (4.2%) | – | 1 (4.2%) | 1 (4.2%) | |
| Skin Cancer | 1 (1.1%) | 1 (4.2%) | – | – | – | |
| Previous Tx | Surgery | 11 (11.6%) | 3 (12.5%) | 2 (8.7%) | 5 (20.8%) | 1 (4.2%) |
| Chemotherapy | 76 (80.0%) | 17 (70.8%) | 17 (73.9%) | 22 (91.7%) | 20 (83.3%) | |
| Radiation Therapy | 71 (74.7%) | 19 (79.2%) | 18 (78.3%) | 17 (70.8%) | 17 (70.8%) | |
| Time | Last cancer Tx to intervention (days) | 1292 | 1587 | 1588 | 1358 | 647 |
| Range (days) | 48–10034 | 136–7071 | 48–10034 | 104–6115 | 112–1957 | |
| Insomniaa | Mean (SD) | 14.1 (4.8) | 14.4 (4.6) | 13.3 (5.8) | 13.6 (3.9) | 15.2 (5.0) |
| QOLb | Mean (SD) | 77.0 (16.6) | 78.9 (15.3) | 79.8 (17.8) | 77.4 (12.9) | 71.9 (19.7) |
NOTE: Data might not add to 100% because of rounding.
Abbreviations: SD, standard deviation; Tx, treatment; QOL, quality of life.
a
By Insomnia Severity Index.
b
By Functional Assessment of Cancer Therapy-General.